Could a pill replace the shot? new study tests oral buprenorphine for opioid treatment

NCT ID NCT06086275

Completed Knowledge-focused Sponsor: Brigham and Women's Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed Phase 1 study tested how the body processes different doses of oral buprenorphine compared to an intravenous dose. Eighteen healthy adults with past opioid use received three different doses in separate visits. Researchers measured drug levels in the blood over 24 hours to understand how oral buprenorphine might be used as a low-dose induction strategy for opioid use disorder.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: buprenorphine
What this could lead to: If successful, this could help develop safer ways to start buprenorphine treatment for opioid use disorder, reducing withdrawal symptoms.
What could go wrong: This is a very early Phase 1 study with only 18 healthy volunteers, not people with opioid use disorder. Results may not apply to real-world patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OPIOID-USE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

opiate dependence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OPIOID-USE DISORDER

Contacts and locations

Locations

Brigham and Women's hospital

Boston, Massachusetts, 02115, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.